A multiple-dose toxicity study of tanezumab in cynomolgus monkeys

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 2, 2011, Pages 334-342

  Zorbas, Mark ^a   Hurst, Susan ^a   Shelton, David ^b   Evans, Mark ^a   Finco, Deborah ^a   Butt, Mark ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

^c Tox Path Specialists   (United States)

Author keywords

Anti drug antibody; Cynomolgus monkey; Nerve growth factor; Pharmacokinetics; Tanezumab; Toxicity

Indexed keywords

DRUG ANTIBODY; TANEZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAPLORHINI; HYPERSENSITIVITY REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; TOXICITY TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; NERVOUS SYSTEM; PAIN; TOXICITY TESTS;

ANIMALIA; MACACA FASCICULARIS;

EID: 79952072290     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.11.005     Document Type: Article

References (29)

1. Abdiche Y.N., Malashock D.S., Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008, 17(8):1326-1335.
2. Angeletti P.U., Levi-Montalcini R., Caramia F. Analysis of the effects of the antiserum to the nerve growth factor in adult mice. Brain Res. 1971, 27(2):343-355.
3. Bjerre B., Wiklund L., Edwards D.C. A study of the de- and regenerative changes in the sympathetic nervous system of the adult mouse after treatment with the antiserum to nerve growth factor. Brain Res. 1975, 92(2):257-278.
4. Chamanza R., Marxfeld H.A., Blanco A.L. Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol. Pathol. 2010, 38(4):642-657.
5. Cohen S. Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc. Natl. Acad. Sci. USA 1960, 46(3):302-311.
6. Della Seta D., de Acetis L., Aloe L., Alleva E. NGF effects on hot plate behaviors in mice. Pharmacol. Biochem. Behav. 1994, 49(3):701-705.
7. Gorin P.D., Johnson E.M. Effects of long-term nerve growth factor deprivation on the nervous system of the adult rat: an experimental autoimmune approach. Brain Res. 1980, 198(1):27-42.
8. Halvorson K.G., Kubota K., Sevcik M.A., et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005, 65(20):9426-9435.
9. Hefti F.F., Rosenthal A., Walicke P.A., et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol. Sci. 2006, 27(2):85-91.
10. Jimenez-Andrade J.M., Martin C.D., Koewler N.J., et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain 2007, 133(1-3):183-196.
11. Johnson E.M., Osborne P.A., Taniuchi M. Destruction of sympathetic and sensory neurons in the developing rat by a monoclonal antibody against the nerve growth factor (NGF) receptor. Brain Res. 1989, 478(1):166-170.
12. Katz N., Borenstein D., Birbara C., et al. Tanezumab, an anti-nerve growth factor antibody, for the treatment of chronic low back pain - a phase 2 trial. J. Pain 2009, 10(Suppl. 4):S42.
13. Koewler N.J., Freeman K.T., Buus R.J., et al. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J. Bone Miner. Res. 2007, 22(11):1732-1742.
14. Lane, N.E., Schnitzer, T.J., Smith, M.D., Brown, M.T., 2008. Efficacy and safety of PF04383119 in treating moderate to severe pain due to osteoarthritis (OA). Ann. Rheum. Dis. 67 (Suppl. II), 237.
15. Lane N., Schnitzer T., Birbara C., et al. Tanezumab for treatment of knee osteoarthritis pain. N. Engl. J. Med. 2010, 363(16):1521-1531.
16. Levi-Montalcini R., Booker B. Destruction of the sympathetic ganglia in mammals by an antiserum to a nerve-growth protein. Proc. Natl. Acad. Sci. USA 1960, 46(3):384-391.
17. Lewin G.R., Ritter A.M., Mendell L.M. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J. Neurosci. 1993, 13(5):2136-2148.
18. Lobo E.D., Hansen R.J., Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2004, 93(11):2645-2668.
19. McMahon S.B., Bennett D.L., Priestley J.V., Shelton D.L. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat. Med. 1995, 1(8):774-780.
20. Ross M., Lofstrandh S., Gorin P.D., Johnson E.M., Schwartz J.P. Use of an experimental autoimmune model to define nerve growth factor dependency of peripheral and central substance P-containing neurons in the rat. J. Neurosci. 1981, 1(11):1304-1311.
21. Ruit K.G., Osborne P.A., Schmidt R.E., Johnson E.M., Snider W.D. Nerve growth factor regulates sympathetic ganglion cell morphology and survival in the adult mouse. J. Neurosci. 1990, 10(7):2412-2419.
22. Sabsovich I., Wei T., Guo T.Z., et al. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138(1):47-60.
23. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 2002, 24:1720-1740.
24. Schwartz J.P., Pearson J., Johnson E.M. Effect of exposure to anti-NGF on sensory neurons of adult rats and guinea pigs. Brain Res. 1982, 244(2):378-381.
25. Sevcik M.A., Ghilardi J.R., Peters C.M., et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005, 115(1-2):128-141.
26. Shelton D.L., Zeller J., Ho W.H., Pons J., Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116(1-2):8-16.
27. Shelton D., Vergara G., Pons J., Ho W.-H., Stratton J. Effect of PF04383119 on post-incisional pain following IV or IP administration. Anesthesiology 2008, 109:A1539.
28. Watson J.J., Allen S.J., Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential?. BioDrugs 2008, 22(6):349-359.
29. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P., Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62(2):327-331.